MedTrace Logo

Curcumin as a Novel Treatment to Improve Cognitive Dysfunction in Schizophrenia

NCT02104752 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 39

Last updated 2019-05-15

Study results available
· View outcomes & findings →

Summary

The investigators propose to test whether curcumin nanoparticles will improve behavioral measures and biomarkers of cognition and neuroplasticity in patients with schizophrenia who are already receiving a stable dose of antipsychotic.

Conditions

Interventions

DRUG

Curcumin

360 mg/day (divided into twice daily oral doses)

DRUG

Placebo

Inactive, matched placebo ("Sugar Pill")

Sponsors & Collaborators

  • Stanley Medical Research Institute

    collaborator OTHER

  • Theravalues, Inc.

    collaborator INDUSTRY

  • University of California, Los Angeles

    collaborator OTHER

  • VA Greater Los Angeles Healthcare System

    lead FED

Principal Investigators

  • Stephen R Marder, M.D. · VA Greater Los Angeles

  • Jonathan K Wynn, Ph.D. · VA Greater Los Angeles

  • Michael C Davis, M.D.,Ph.D. · VA Greater Los Angeles

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2016-05-31
Completion
2017-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02104752 on ClinicalTrials.gov